20 studies found for:    Open Studies | "Thymus Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size
Conditions: Primary Inoperable Thymoma;   Local Recurrent Thymoma
Intervention: Drug: SOM230 LAR
2 Recruiting Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Conditions: Thymoma;   Thymus Neoplasms
Intervention: Drug: Sunitinib
3 Recruiting Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies
Conditions: Non Small Cell Lung Cancer;   Small Cell Lung Cancer;   Thymoma;   Thymus Neoplasms
Intervention: Radiation: Esophageal sparing IMRT
4 Recruiting Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
Condition: Thymoma
Intervention: Radiation: radiotherapy
5 Recruiting Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy
Condition: Malignant Thymoma
Intervention: Drug: Milciclib Maleate
6 Recruiting Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Condition: Thymoma and Thymic Carcinoma
Intervention: Drug: Everolimus
7 Not yet recruiting A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Condition: Thymoma
Intervention: Drug: BKM120
8 Recruiting Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Conditions: Thymoma;   Thymic Carcinoma.;   Clinical Masaoka Stage II-IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
9 Recruiting Nonmyeloablative Allogeneic Transplant
Conditions: Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Mantle Cell Lymphoma;   Multiple Myeloma;   Waldenstrom Macroglobulinemia;   Breast Cancer;   Renal Cell Carcinoma;   Melanoma;   Sarcoma;   Ovarian Cancer;   Thymoma
Intervention: Procedure: Nonmyeloablative Allogeneic Transplant
10 Recruiting Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
Conditions: Lymphoma;   Malignant Mesothelioma;   Malignant Pericardial Effusion;   Malignant Pleural Effusion;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Soft Tissue Sarcoma;   Thymoma and Thymic Carcinoma
Interventions: Drug: doxepin hydrochloride;   Other: placebo;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: laboratory procedure
11 Not yet recruiting Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy
Conditions: Lung Metastases;   Recurrent Malignant Mesothelioma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Thymoma and Thymic Carcinoma
Intervention: Radiation: proton beam radiation therapy
12 Recruiting A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Conditions: Thymoma;   Thymus Cancer;   Thymic Carcinoma
Intervention: Drug: Amrubicin
13 Recruiting Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
14 Recruiting Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
Condition: Thymic Carcinoma
Intervention: Drug: Milciclib Maleate
15 Recruiting Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Conditions: Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Sarcoma;   Thymic Carcinoma
Interventions: Biological: H1299 Lysate Vaccine;   Drug: Cyclophosphamide;   Drug: Celecoxib
16 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
17 Recruiting Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals.
Conditions: Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer
Intervention:
18 Recruiting Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
Condition: Locally Advanced Stage III or IV Thymic Cancer
Intervention: Drug: neoadjuvant docetaxel/cisplatin
19 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Intervention:
20 Recruiting Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Conditions: Mesolthelioma;   Esophageal Cancer;   Lung Cancer;   Thoracic Sarcomas
Interventions: Drug: Celecoxib;   Drug: ISCOMATRIX (TM) Adjuvant;   Biological: Autologous Tumor Cell Vaccine

Indicates status has not been verified in more than two years